Novo Nordisk has called on the Patent Trial and Appeal Board (PTAB) to impose sanctions on Mylan for allegedly breaching an explicit commitment. The contention arises from Mylan’s bid to invalidate a patent related to Ozempic, Novo Nordisk’s high-revenue diabetes and weight loss medication, in the Delaware district court. This move allegedly breaks Mylan’s prior pledge not to pursue such claims. Novo Nordisk’s actions underscore the pivotal role of legal commitments in ongoing patent disputes.
For more details on this development, visit the article by Law360.